Development and Characterization of Nanoliposomal Hydroxyurea Against BT-474 Breast Cancer Cells

Purpose: Hydroxyurea (HU) is a well-known chemotherapy drug with several side effects which limit its clinical application. This study was conducted to improve its therapeutic efficiency against breast cancer using liposomes as FDA-approved drug carriers. Methods: PEGylated nanoliposomes-containing...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Adv Pharm Bull
Päätekijät: Akbari, Azam, Akbarzadeh, Azim, Rafiee Tehrani, Morteza, Ahangari Cohan, Reza, Chiani, Mohsen, Mehrabi, Mohammad Reza
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Tabriz University of Medical Sciences 2020
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6983993/
https://ncbi.nlm.nih.gov/pubmed/32002360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15171/apb.2020.005
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia